Drug intelligence / Profile preview

AP017

Development stage: Unknown
Lead developer: Anyuan Pharmaceutical Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (injection)

Overview

AP017 is a monoclonal antibody developed by Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. It is currently in Phase 1 clinical development, with its primary indications being Hemophilia A and Hemophilia B. The drug is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics in healthy subjects through single-dose escalation studies. The precise molecular target and mechanism of action have not been disclosed publicly as of the latest available data[1].

Other names: AP017单克隆抗体

Beyond the preview

Go deeper on AP017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP017.

Explore the full profile